Amisulpride - Acacia Pharma

Drug Profile

Amisulpride - Acacia Pharma

Alternative Names: APD-403; APD-421; BAREMSISTM

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acacia Pharma
  • Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative nausea and vomiting
  • Phase II Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 15 Mar 2018 Interim efficacy and adverse events data from a phase III prophylaxis trial in Postoperative nausea and vomiting released by Acacia Pharma
  • 04 Jan 2018 FDA accepts NDA for amisulpride for Postoperative nausea and vomiting (Rescue treatment, Prevention, Monotherapy, Combination Therapy) for review
  • 04 Jan 2018 Preregistration for Postoperative nausea and vomiting (Combination therapy, Prevention) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top